Fani Deapsari

Fani Deapsari

Auto-generated profile, based on publicly available information

Fani Deapsari

Doctoral Program of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2025 in European Journal of Dentistry
Verified
Journal Article
Open access
PDF file
YPYusuf Alif Pratama
Yusuf Alif Pratama
HMHoney Dzikri Marhaeny
Honey Dzikri Marhaeny
FDFani Deapsari
Fani Deapsari
ABAniek Setiya Budiatin
Aniek Setiya Budiatin
MRMahardian Rahmadi
Mahardian Rahmadi
JKJunaidi Khotib
Junaidi Khotib
Over the past decade, the occurrence of bone defects has seen a notable rise. In both developed and developing nations, their prevalence tends to increase in parallel with population density and levels of physical activity. Various therapeutic approaches have been implemented to address bone fractures, focusing on preventing infections, promoting faster healing, and restoring normal bone function. Among these, bone grafting—a surgical technique involving the use of biomaterials—remains a widely utilized method for bone replacement. This review aims to identify biomaterials that have biocompatibility with bone, osteoinductive, and osteoconductive properties so that they can trigger good osteogenesis. This review is based on a compilation of publications from various databases related to factors affecting the process of bone ossification. This study also evaluates the characteristics of hydroxyapatite biomaterials that play a role in inducing osteogenesis. The phosphate/calcium ratio close to 1.67, porosity in the range of 40 to 60%, pore diameter of 200 to 900 nm, and crystallinity of 40 to 60% will help the osteogenesis to perform well. The results of this study highlight the advantages of hydroxyapatite in terms of its osteoconductive, osteoinductive, and osteointegrative properties, which can trigger osteogenesis.

21 April 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FDFani Deapsari
Fani Deapsari
YPYusuf Alif Pratama
Yusuf Alif Pratama
HAHazna Mariskha Afra
Hazna Mariskha Afra
ASAdisti Ratna Sari
Adisti Ratna Sari
HPHanni Prihhastuti Puspitasari
Hanni Prihhastuti Puspitasari
ABAniek Setiya Budiatin
Aniek Setiya Budiatin
Osteoarthritis (OA) is a degenerative joint disease marked by cartilage degradation and subchondral bone remodeling, while most nutraceuticals focus on cartilage and overlook bone health. We developed a capsule containing bovine hydroxyapatite (BHA), gelatin, vitamin D₃, and chondroitin sulfate and evaluated its physicochemical quality and in vivo effectiveness. Formulations were tested for organoleptic properties, moisture, weight uniformity, disintegration time, microbial contamination, heavy metals, and active-ingredient identification in accordance with Indonesian Food and Drug Agency regulations; all specifications were met. Efficacy was assessed in a rabbit osteochondral defect model (post-traumatic degeneration/repair model) with negative control, positive control, and test groups treated for 28 days, followed by radiography, histology (H&E quantification of osteoblasts, osteoclasts, osteocytes, and chondrocytes), and immunohistochemistry (type II collagen and MMP-13). Compared with untreated controls, the test group showed improved cartilage architecture, higher osteoblast, osteocyte, and chondrocyte counts, fewer osteoclasts, increased type II collagen expression, and reduced MMP-13, with outcomes comparable or superior to the positive control. These findings indicate the formulated nutraceutical supports both cartilage and subchondral bone and may serve as a complementary strategy for OA management, warranting confirmation in longer, dose-responsive, and translational studies.